The Indian patent office granted a patent to Mr. Achal Agrawal, a researcher and a pharma entrepreneur. The patent relating to the field of chemistry is titled “Novel Improved Method for Synthesis of Diaminophenothiazine Compounds”. The patent concerns a novel process for synthesizing the compound “Methylthioninium Chloride” or “Methylene Blue”.
Methylene Blue is the first phenothiazine compound that was developed more than 140 years ago. It has a plethora of medicinal applications that have been under research since. The compound is already approved for treating a blood disorder called methemoglobinemia. Methylene Blue is currently under clinical trial for its experimental use in the treatment of Alzheimer’s disease. In 2008, a Phase II clinical trial concluded that a purified form of methylene blue slowed cognitive decline in people with mild to moderate Alzheimer’s disease. Antimalarial use of the drug has recently been revived. It is also being studied as a photosensitizer for non-invasive photodynamic therapy of cancers.
“I have been successfully using nebulized methylene blue for over a decade to treat lung infections and fibrosis for my patients. During the first and the second wave of COVID-19, I extensively used methylene blue based on my past experience. In low dosage, methylene blue works against COVID-19 as a prophylactic as well as a treatment for mild to moderate COVID patients when administered sublingually & through nebulization.” Says Dr. Deepak Golwalkar, veteran Pulmonologist.
“Methylene Blue being such an old compound having a history of more than a hundred years is hardly available in required pharmaceutical grade and purity. Even in developed countries like the United States, there is only a single source of this life-saving medicine. It is really difficult to synthesize methylene blue in high purity because of the degradants formed during the oxidation process. Looking at a large number of upcoming pharmaceutical applications of this compound, the new short process for yielding a high purity compound will be really beneficial for our industry.”, says Mr. Achal Agrawal, CEO of Macsen Labs, and inventor of the patented process.
The inventive process which has been patented yields a high purity compound in minimal steps and has eliminated lengthy purification procedures. Also, the process employs water-based chemistry that excludes the use of harmful chemical solvents, thus further eliminating the probability of occurrence of known or unknown impurities. The methylene blue compound that is obtained from Mr. Agrawal’s inventive process is of 99% purity and meets the Global Pharmacopoeia quality requirements established by compendiums such as United States Pharmacopoeia and European Pharmacopoeia (Ph. Eur.).
During the second wave of COVID-19, Macsen group also applied for emergency use of this drug with the CDSCO, but the emergency use was not granted without conducting clinical trials. Methylene Blue is not yet approved for any other disease apart from Methemoglobinemia, and it is a prescription drug that should not be consumed without advice from a medical professional.
Macsen Laboratories was started as a household unit on a rooftop in the old quarters of the historic walled city of Udaipur, by Dr. Mohanlal Agrawal, Mr.Puranmal Agrawal & Mr. Chandra Sen Agrawal in 1952. It is engaged in the manufacturing of niche active pharmaceutical ingredients, pharmaceutical application dyes, compounds of precious and rare earth metals, and other specialty inorganic compounds. Currently, Macsen Labs group is headquartered in Udaipur (Rajasthan, India), and has various manufacturing units in and around Udaipur.
Mr. Achal Agrawal is the current CEO of Macsen Group. He is the fourth-generation entrepreneur of the family owned Macsen Labs Group, and has been leading the organization since 2008. He has studied Chemical Engineering from Pune University, and he holds a keen interest in practical science, research, robotics, and aviation. Under his leadership Macsen Labs which was a single manufacturing unit, has become a group of industries, and the group’s turnover has increased substantially.
India grants patent to Macsen Labs’ Methylene Blue Synthesis Process
Macsen Labs’ Methylene Blue Synthesis Process receives Indian patent
Macsen Labs is a manufacturer and supplier of several grades of Methylene Blue such as:-
- Methylene Blue USP
- Methylene Blue Zinc Free
- Methylene Blue BP 2000
- Methylene Blue BP 1973
- Methylthioninium Chloride BP
- Methylthioninium Chloride EP 9.0
- Methylthioninium Chloride E.P-10
Resources on Methylene Blue
What is Methylene Blue | An Overview of Methylene Blue
Methylene blue for treating Methemoglobinemia
Methylene Blue & Covid-19 – Research So Far
Staining with Methylene Blue | Different uses and examples
Methylene Blue’s uses in Fish Aquaculture
Common Side Effects of Methylene Blue & Precautions to be taken
Methylene Blue Against Cyanide Poisoning
Methylene Blue Injection : Indications, Dosage & Brands
Methylene Blue in the treatment of Alzheimer’s